Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Amyndas Phamaceuticals LLC
DescriptionCompstatin-derived complement 3 (C3) inhibitor
Molecular Target Complement 3 (C3)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationParoxysmal nocturnal hemoglobinuria (PNH)
Indication DetailsTreat paroxysmal nocturnal hemoglobinuria (PNH)
Regulatory Designation U.S. - Orphan Drug (Treat paroxysmal nocturnal hemoglobinuria (PNH));
EU - Orphan Drug (Treat paroxysmal nocturnal hemoglobinuria (PNH))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today